Literature DB >> 35274160

Successful management of segmental zoster paresis on the upper arm with temporally burst spinal cord stimulation.

Keisuke Yamaguchi1, Chika Kawabe-Ishibashi2, Shie Iida2, Takayuki Saito2, Tomokazu Takakura3.   

Abstract

Segmental zoster paresis (SZP) of the limbs is characterized by a focal, asymmetric neurogenic weakness that may occur in an extremity affected by herpes zoster (HZ). In this case report, we describe the case of a patient with SZP who presented with these problems and responded well to temporary spinal cord stimulation (SCS) and systematic rehabilitation. A 62-year-old female patient was referred for right upper limb pain, weakness, and insomnia due to pain. After completing the 14-day trial stimulation, the pain numerical rating scale of the patient in the right upper extremity decreased from 8/10 to 2/10. The Athens insomnia scale score decreased from 15/24 to 10/24. Furthermore, the grip strength of the right hands increased from 6.7 to 16.8 kg at discharge. We induced temporal SCS and rehabilitation of the right upper limb SZP and successfully reduced the pain. An in-depth understanding of the neurological complications secondary to HZ should be emphasized, with temporal SCS and rehabilitation expected to play a crucial role in the motor recovery of patients with SZP.
© 2022. The Author(s) under exclusive licence to Japanese Society of Anesthesiologists.

Entities:  

Keywords:  Burst spinal cord stimulation; Herpes zoster; Rehabilitation; Segmental zoster paresis

Mesh:

Year:  2022        PMID: 35274160     DOI: 10.1007/s00540-022-03056-5

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.931


  16 in total

1.  Acute pain in herpes zoster and its impact on health-related quality of life.

Authors:  Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin
Journal:  Clin Infect Dis       Date:  2004-07-19       Impact factor: 9.079

2.  Segmental zoster paresis of the left upper limb in a pediatric patient.

Authors:  Lisa M Ruppert; Megan L Freeland; Michael D Stubblefield
Journal:  Am J Phys Med Rehabil       Date:  2010-12       Impact factor: 2.159

3.  Segmental zoster paresis of the upper extremity: a case report.

Authors:  Ozlem Yoleri; Neşe Olmez; Ibrahim Oztura; Ilker Sengül; Rezzan Günaydin; Asuman Memiş
Journal:  Arch Phys Med Rehabil       Date:  2005-07       Impact factor: 3.966

Review 4.  Segmental zoster paresis of limbs.

Authors:  M P Merchut; G Gruener
Journal:  Electromyogr Clin Neurophysiol       Date:  1996-09

5.  Studies on the pathogenesis of neurological diseases associated with Varicella-Zoster virus.

Authors:  P G Kennedy; J D Barrass; D I Graham; G B Clements
Journal:  Neuropathol Appl Neurobiol       Date:  1990-08       Impact factor: 8.090

6.  Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey.

Authors:  Gerry Oster; Gale Harding; Ellen Dukes; John Edelsberg; Paul D Cleary
Journal:  J Pain       Date:  2005-06       Impact factor: 5.820

Review 7.  Central mechanisms of pathological pain.

Authors:  Rohini Kuner
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

8.  Segmental zoster paresis of limbs: report of three cases and review of literature.

Authors:  Sumihiro Kawajiri; Momo Tani; Kazuyuki Noda; Kenji Fujishima; Nobutaka Hattori; Yasuyuki Okuma
Journal:  Neurologist       Date:  2007-09       Impact factor: 1.398

9.  The effects of temporary spinal cord stimulation (or spinal nerve root stimulation) on the management of early postherpetic neuralgia from one to six months of its onset.

Authors:  Fujio Yanamoto; Kazushige Murakawa
Journal:  Neuromodulation       Date:  2012-02-29

10.  A retrospective case series of segmental zoster paresis of limbs: clinical, electrophysiological and imaging characteristics.

Authors:  Ying Liu; Bing-Yun Wu; Zhen-Shen Ma; Juan-Juan Xu; Bing Yang; Heng Li; Rui-Sheng Duan
Journal:  BMC Neurol       Date:  2018-08-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.